Display options
Share it on

Catheter Cardiovasc Interv. 2021 Mar;97(4):612-613. doi: 10.1002/ccd.29571.

The challenges of coronary no-reflow phenomenon.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions

Brian C Case, Lowell F Satler

Affiliations

  1. Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

PMID: 33721406 DOI: 10.1002/ccd.29571

[No abstract available.]

References

  1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke Statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133:e38-e360. - PubMed
  2. Rezkalla SH, Stankowski RV, Hanna J, Kloner RA. Management of no-Reflow Phenomenon in the catheterization laboratory. JACC Cardiovasc Interv. 2017;10:215-223. - PubMed
  3. Navarese EP, Frediani L, Kandzari DE, et al. Efficacy and safety of intracoronary epinephrine versus conventional treatments alone in STEMI patients with refractory coronary no-reflow during primary PCI: the RESTORE observational study. Catheter Cardiovasc Interv. 2021;97:602-611. - PubMed
  4. Huang RI, Patel P, Walinsky P, et al. Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention. Catheter Cardiovasc Interv. 2006;68:671-676. - PubMed
  5. Aksu T, Guler TE, Colak A, et al. Intracoronary epinephrine in the treatment of refractory no-reflow after primary percutaneous coronary intervention: a retrospective study. BMC Cardiovasc Disord. 2015;15:10. - PubMed

MeSH terms

Publication Types